MedTrace Logo

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

NCT00038376 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2018-10-29

No results posted yet for this study

Summary

The purpose of this study is to determine the response rate of patients with T-cell malignancies to combination therapy using interferon-alpha (Roferon) and Isotretinoin (Accutane).

Conditions

  • Lymphoma, T-Cell
  • Mycosis Fungoides
  • Hematologic Neoplasms

Interventions

DRUG

Isotretinoin (Accutane)

0.5 mg/k (1.0 mg/k total) by mouth twice a day

DRUG

Interferon Alpha

Starting dose of 3 MU injected under skin once a day for 12 weeks.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Razelle Kurzrock, MD, BS · UT MD Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1990-05-08
Primary Completion
2005-06-30
Completion
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00038376 on ClinicalTrials.gov